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Abstract: Therapeutic agents targeting bacterial virulence factors are gaining interest as 
non-antibiotic alternatives for the treatment of infectious diseases. Clostridium difficile is a 
Gram-positive pathogen that produces two primary virulence factors, enterotoxins A and B 
(TcdA and TcdB), which are responsible for Clostridium difficile-associated disease 
(CDAD) and are targets for CDAD therapy. Antibodies specific for TcdA and TcdB have 
been shown to effectively treat CDAD and prevent disease relapse in animal models and in 
humans. This review summarizes the various toxin-specific antibody formats and strategies 
under development, and discusses future directions for CDAD immunotherapy, including 
the use of engineered antibody fragments with robust biophysical properties for systemic 
and oral delivery. 
Keywords: Clostridium difficile; Clostridium difficile-associated disease; toxin; antibody; 
single-domain antibody; neutralization; therapy 
 
1. Introduction 
Clostridium difficile is a Gram-positive, endospore-forming, anaerobic, gastrointestinal pathogen 
that is a leading cause of nosocomial infections in developed nations. The bacterium is transmitted by 
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the fecal-oral route and can readily colonize persons with suppressed microflora as a result of 
antibiotic usage. The symptoms of C. difficile infection range from mild cases of diarrhea to fatal 
pseudomembranous colitis and are collectively known as C. difficile-associated disease (CDAD) [1–3]. 
The recent emergence of hypervirulent and antibiotic-resistant C. difficile strains with increased 
morbidity, mortality and recurrence rates [4,5] have warranted the development of novel, non-antibiotic 
based treatment regimes. C. difficile exerts its pathological effects by colonizing luminal surfaces of 
the colon and secreting two high-molecular weight exotoxins, toxin A (TcdA) and toxin B (TcdB). 
With their causative role in CDAD firmly established [6–9], these two virulence factors have been 
identified as targets for therapeutic intervention. With the continued rise of antibiotic resistance, the 
development of novel, non-antibiotic agents, which target bacterial virulence factors and reduce the 
selection pressure normally placed upon pathogens by antibiotics, are highly desirable [10–12]. These 
agents, such as antibodies, may also be useful to control the recurrence of infection after antibiotic 
treatment has been terminated. 
2. Toxin Structure and Function 
Similar to other members of the large clostridial family of toxins, TcdA and TcdB target the 
Rho/Ras superfamily of GTPases by irreversible modification through glucosylation [13,14]. Since 
GTPases are key cellular regulatory proteins, their permanent inactivation causes disruptions in 
essential cell signaling pathways that are critical for transcriptional regulation, apoptosis, cytoskeleton 
integrity and eventually colonic epithelial cell barrier function [15,16]. 
Before C. difficile can exert a physiological effect on a host, the pathogen must colonize the host. It 
is believed that C. difficile spores are consumed orally and travel to the large intestine where they 
flourish in environments lacking competition from normal gut microflora. Surface layer proteins 
(SLPs), which decorate the pathogen’s surface, are involved in adherence to the human intestinal 
epithelium and are thought to be a critical step in gut colonization [17]. Quorum sensing molecules 
have been shown to play an important role in transcriptional regulation of toxin production [18] 
suggesting toxin production is a cell-density dependent process. Whether C. difficile toxin production 
and secretion occurs during or after colonization of the host is unknown. 
TcdA and TcdB are single-polypeptide chain, high-molecular weight exotoxins (308 kDa and   
269 kDa, respectively) organized into multi-domain structures [13,19]. The genes encoding TcdA and 
TcdB, tcdA and tcdB, are located in the 19.6 kb C. difficile pathogenicity locus (PaLoc) and are 
positively regulated at the protein level by TcdR [14]. Like other members of the large clostridial toxin 
family, TcdA and TcdB are organized as modular domains with each domain performing a distinct 
function (Figure 1). The C-terminal region of TcdA/B is responsible for toxin binding to the surface of 
epithelial cells possibly via multi-valent interactions with putative cell-surface carbohydrate   
receptors [20,21]. Structural studies of this cell receptor binding domain (RBD) from TcdA and TcdB 
revealed a β-solenoid fold [19,22] with seven carbohydrate binding sites identified for receptor binding 
in TcdA [21,22]. While the C-terminal region of TcdA has been shown to bind various 
oligosaccharides, including the trisaccharide α-Gal-(1,3)-β-Gal-(1,4)-β-GlcNac [23], the native human 
ligand has not been positively identified. The TcdB host cell receptor also remains unknown. Binding 
of TcdA/B via the RBD to epithelial cells induces receptor-mediated endocytosis, permitting entry of Toxins 2010, 2                 
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the endosome-encapsulated toxin into the cytoplasm (Figure 2). Once internalized, the toxins require 
an acidic endosome for transport to the cytosol. A decrease in endosomal pH is thought to induce a 
conformational change, resulting in exposure of the hydrophobic membrane insertion (MI) domain and 
insertion of the N-terminus (catalytic domain and cysteine protease domain) into and through the 
endosomal membrane via pore formation [13]. Recently, Reineke et al. [24] showed inositol 
hexakisphosphate (InsP6) from the host cell induces the autocatalytic cleavage of the N-terminal 
region at the cysteine protease (CP) site, freeing the N-terminal glucosyltransferase (GT) domain into 
the cytosol while the remaining portions of the toxin is left in the endosome. This finding was later 
supported by evidence from Egerer et al. [25]. Upon cleavage, the GT domain is capable of 
transferring glucose residues from UDP-glucose to Rho-GTPases [26], locking the important cell 
signaling mechanism in an inactive conformation. Inhibition of Rho-GTPases causes a series of 
cascading effects, including dysregulation of actin cytoskeleton and tight junction integrity. 
Collectively, these events lead to increased membrane permeability and loss of barrier function [27], 
diarrhea, inflammation, and a massive influx of neutrophils and other members of the innate   
immune response [2].  
Figure 1. Schematic representation of Clostridium difficile toxin A and B. For illustration 
purposes, only one toxin is shown. Toxin A (TcdA, 308 kDa) and toxin B (TcdB,   
269 kDa) are each composed of four domains, which perform distinct functions. The 
schematic illustrates each domain, their function, and site of action.   
GT = glucosyltransferase domain, CP = cysteine protease domain, MI = hydrophobic 
membrane insertion domain, RBD = cell-receptor binding domain.  
 
3. Treatment of Clostridium difficile-Associated Disease 
The most common treatment for C. difficile infection currently involves discontinuing the original 
antibiotic in use at the time of diagnosis followed by administration of vancomycin or metronidazole 
antibiotics. However, resistant strains to both antibiotics have been reported [28,29]. In addition, 
increased CDAD recurrence rates and the prominence of hypervirulent strains over expressing TcdA 
and TcdB [4,5] highlight the need for novel approaches to treatment. There are several strategies under 
development for the treatment of CDAD (Table 1), including: various antibiotics, replenishment of 
patient microflora with oral probiotic therapy or fecal-transplantation therapy, development of toxin 
binding resins and polymers, vaccines, and toxin-specific antibodies and recombinant antibody 
fragments [2,30–33]. In this review, we focus on efforts to develop anti-TcdA/B antibodies for CDAD 
immunotherapy, report the successes and failures, and describe the challenges that lie ahead. Toxins 2010, 2                 
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Figure 2. Schematic illustration of Clostridium difficile toxin mechanism of action. TcdA 
or TcdB first binds the surface of epithelial cells via the RBD region of the toxin, 
promoting receptor-mediated endocytosis. Acidification of the endosome-encapsulated 
toxin promotes a conformational change in which the N-terminal region of the toxin is 
extended through the endosomal membrane into the cytoplasm. Cellular inositol 
hexakisphosphate (InsP6) promotes cleavage at the start of the CP domain, releasing the 
GT domain into the cytoplasm. The GT domain transfers a glucose moiety from   
UDP-glucose to a threonine (T) residue on Rho-GTPase, trapping the signaling enzyme in 
an inactive conformation. Targeting the RBD domain with antibodies and antibody fragments 
may block toxin binding to cell-surface receptors or prevent internalization of the toxin. 
 
Table 1. Therapeutic strategies under development for the treatment of CDAD. 
Type Description  Reference 
Antibiotic  Nitazoxanide  [34] 
  Rifaximin  [35] 
  Ramoplanin  [36] 
  Difimicin  [37] 
Probiotic  Saccharomyces boulardii  [38] 
  Lactobacillus spp.  [39] 
Fecal transplantation  Stool replacement therapy  [40] 
Toxin binding agents  Cholestyramine  [41] 
 Tolevamer  [42] 
Vaccine  Toxoid-based  [43] 
  SLP-based  [44] 
  DNA-based  [45] 
Antibodies  IgG, IgA, IgY, polyclonal  See Tables 2 and 3 
 scFv  [46] 
  sdAb [47] 
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4. Toxin-Specific Antibodies 
The field of antibody engineering has rapidly expanded over the past few decades, proving itself as a 
source for high-affinity, high-specificity, protein-based binding reagents for a myriad of applications 
[48]. From polyclonal antibody production in animals, to hybridoma cell culture of IgG antibodies, to 
the rational design of high-affinity antibodies and antibody fragments via display techniques and site-
directed mutagenesis, antibodies have been produced by numerous methods and against countless 
targets of therapeutic importance. Of the FDA-approved therapeutic antibodies on the market most are 
for the treatment of cancer and autoimmune disorders, although numerous antibodies targeting the 
virulence factors of disease-causing bacteria are in development and in clinical trials. 
With respect to C. difficile, administering toxin-neutralizing antibodies for CDAD therapy is 
supported by numerous studies which have shown that patients with low anti-toxin IgG titers are more 
likely to experience severe effects from C. difficile infection and are more likely to develop recurrent 
rounds of CDAD.  
4.1. Role of antibodies in CDAD 
Persons infected with C. difficile experience a broad-spectrum of symptoms, ranging from 
asymptomatic carriage to life-threatening pseudomembraneous colitis. The reasons for such varied 
symptoms, or lack thereof, is not fully understood. It is believed that patients who experience mild 
cases of CDAD tend to possess high anti-toxin A IgG serum titers [49–51]. Conversely, patients 
susceptible to relapsing C. difficile infection have demonstrated low anti-TcdA Ig titers, specifically 
IgM, IgG2 and IgG3 isotypes [49,52,53]. TcdA-neutralizing secretory IgA (sIgA) antibodies are also 
thought to play a role in regulating CDAD severity in the colonic mucosa [54,55]. Furthermore, many 
individuals develop anti-toxin A/B antibodies (i.e., IgG, IgA) in the serum [51,56] and stool after a 
symptomatic CDAD infection [57]. The importance of anti-toxin Abs in regulating CDAD severity 
and relapse is highlight by the number of experimental vaccines under development. For example, 
toxoid-based vaccines have protected animals against C. difficile challenge [57]. Others have shown 
antibody-mediated protection can be transferred from adult hamsters to offspring through milk [8,58]. 
Therefore, the introduction of anti-toxin antibodies to patients suffering from severe C. difficile 
infection may be a useful approach to treat severe CDAD or reduce the incidence of recurrent   
CDAD infection. 
4.2. Experimental animal studies  
Over the past 30 years, a number of antibodies (Abs) have been isolated against C. difficile toxins 
and their efficacy evaluated in various animal models (Figure 3; Table 2). Some of the earliest 
evidence that anti-toxin antibodies may be useful agents for C. difficile therapy was demonstrated by 
Allo et al. [59] who isolated C. sordellii toxin-specific polyclonal Abs and found intraperitoneal (I.P.) 
injection of these Abs into hamsters prevented clindamycin-induced C. difficile-associated colitis. The 
earliest animal study involving monoclonal antibodies (mAbs) specific for TcdA and TcdB was 
performed by Lyerly et al. [60]. This group demonstrated that pre-mixing anti-TcdA mAb PCG-4 with 
TcdA and orally administering the mixture completely protected hamsters from fatal doses of TcdA. Toxins 2010, 2                 
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However, administration of G-2 IgG, an antibody which cross-reacted with both toxins, failed to 
protect hamsters against oral TcdA challenge and was not capable of TcdB neutralizing in vitro. 
Elsewhere, Kamiya et al. [61] isolated a panel of nine TcdA-specific mAbs from hybridoma cell lines, 
but found none were capable of preventing mouse lethality upon I.P. co-injection of TcdA and mAb. 
Corthier et al. [62] later isolated three TcdA-specific mAbs (A9, 141-2, and C11) and found the 
antibodies to completely protect mice when injected intravenously four days prior to C. difficile 
challenge. This panel of mAbs was not tested in C. difficile post-challenge treatment models however. 
Interestingly, these three mAbs and PCG-4 produced by Lyerly et al. [60] were shown to recognize the 
C-terminal cell-receptor binding domain region of TcdA, indicating the antibodies may have blocked 
toxin-cell contacts or prevented internalization of the toxin (Figure 2). 
Figure 3. Various antibody formats for anti-toxin therapy. Traditional antibody formats 
(i.e., IgY, IgG, IgA) targeting C. difficile toxins have been produced primarily from 
immunized animals. Smaller recombinant antibody binding fragments (i.e., Fab, scFv, VL, 
VH, VHH) produced from in vitro selection procedures may be useful agents to explore for 
CDAD immunotherapy. Of these recombinant fragments, single-domain antibodies   
(i.e., VHH) from Camelidae heavy-chain IgGs possess inherent thermal and protease 
stability and have been shown to bind cryptic epitopes or pockets on proteins that cannot be 
accessed by traditional antibodies. As such, these single-domain antibodies may be potent 
toxin neutralizers and promising therapeutic agents for CDAD immunotherapy. Black bars 
represent disulfide bonds, grey bars represent hinge regions, and the red bar represents a 
synthetic linker. Some Igs have more than two inter-heavy chain disulfide linkages. 
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Table 2. Animal studies involving C. difficile toxin-specific antibodies. 
Antibody Specificity  Immunogen Antibody  Source  Animal 
Model  Challenge Type  Ab Administration 
Route   Treatment Type  Outcome  Ref. 
PCG-4 IgG  TcdA  Culture 
filtrate  Mouse  Hamster  Oral TcdA administration  Oral   Ab + TcdA co-
administered  Protection   [60] 
G-2 IgG  TcdA and 
TcdB  Toxoid B  Mouse hybridoma  Hamster  Oral TcdA administration  Oral  Ab + TcdA co-
administered 
No 
protection  [60] 
37B5 IgG  TcdA  Toxoid A  Hybridoma  Mouse  I.P. TcdA administration  I.P.  Ab + TcdA co-
administered 
No 
protection  [61] 
A9, 141-2, 
C11 IgGs  TcdA Toxoid  A  Mouse  Mouse  Oral  C. difficile 
1 I.V.  Prophylactic  Protection    [62] 
Bovine Ig  TcdA and 
TcdB 
Culture 
filtrate  Cow colostrum  Hamster  Oral C. difficile (10
8 cells)   Oral   Prophylactic  Protection   [63] 
Bovine Ig  TcdA and 
TcdB 
Culture 
filtrate  Cow colostrum  Rat  CD filtrate into ileum 
2 Ileum  injection 
2  Ab + toxin co-injected 
2 Protection  [64] 
Anti-TcdA 
Bovine Ig  TcdA  Toxoid A  Cow colostrum  Rat  CD filtrate into ileum 
2  Ileum injection 
2  Ab + toxin co-injected 
2  Protection  [64] 
Anti-TcdA 
IgY  TcdA  rTcdA 
fragment  Chicken Hamster  Oral  C. difficile (10
4 cells)  Oral  Treatment and relapse  Protection   [65] 
Anti-TcdB 
IgY  TcdB  rTcdB 
fragment  Chicken  Hamster  Oral C. difficile (10
4 cells)  Oral  Treatment and relapse  Protection   [65] 
Polyclonal   TcdA and 
TcdB 
rTcdA/B 
toxoid  Mouse Hamster  Oral  C. difficile (10
5 cells)  I.P.  Prophylactic  Protection   [66] 
Bovine 
immune whey 
TcdA and 
TcdB 
Culture 
filtrate  Cow   Hamster  Oral C. difficile (10
4 cells)  Oral  Prophylactic and 
treatment  Protection   [67] 
CDA1 IgG  TcdA  Toxoid A  Mouse hybridoma 
3 Hamster  Oral  C. difficile spores (140) 
4  I.P.  Treatment and relapse  Protection   [7] 
MDX-1388 
IgG  TcdB  rTcdB 
fragment  Mouse hybridoma 
3  Hamster  Oral C. difficile spores (140K) 
4  I.P.  Treatment and relapse  Protection   [7] 
1. Number of C. difficile cells administered was not given. 
2. C. difficile (CD) culture filtrates containing TcdA and TcdB were co-injected into rat ileal loops with anti-toxin  
bovine Ig. 
3. Mouse hybridoma cells were generated from HuMAb mice. HuMAb mice are transgenic mice containing human immunoglobulin genes. 
4. One-hundred and forty 
(140) C. difficile spores were given orally in the treatment model, while 140,000 (140 K) C. difficile spores were given orally in the relapse model. I.P. = intraperitoneal.  
I.V. = intravenous. Toxins 2010, 2                 
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Table 3. Therapeutic human studies involving C. difficile toxin-specific antibodies. 
Antibody Specificity  Source 
Administration 
Route 
Number of Treated 
Patients 
Treatment 
Success Rate (%) 
Ref 
IVIG prep  TcdA  Human  I.V.  5  100  [53] 
IVIG prep  TcdA and TcdB  Human  I.V.  2  100  [68] 
IVIG prep  unknown  Human  I.V.  4  100  [69] 
IVIG prep  unknown  Human  I.V.  5  60  [70] 
IVIG prep  unknown  Human  I.V.  14  64  [71] 
IVIG prep  unknown  Human  I.V.  1  100  [72] 
IVIG prep  unknown  Human  I.V.  18  83  [76] 
IVIG prep  unknown  Human  I.V.  1  100  [73] 
IVIG prep  unknown  Human  I.V.  1  100  [74] 
IVIG prep  unknown  Human  I.V.  2  100  [75] 
IVIG prep  unknown  Human  I.V.  21  43  [77] 
IgA  unknown  Human  Oral  1  100  [78] 
Bovine immune 
whey 
TcdA and TcdB  Cow  Oral  15  93  [67] 
Bovine immune 
whey 
TcdA and TcdB  Cow  Oral  101  90  [79] 
Bovine immune 
whey 
TcdA and TcdB  Cow  Oral  20  55  [80] 
CDA1 IgG  TcdA 
Mouse 
hybridoma 
1 
I.V.  101  93  [81] 
CDB1 IgG  TcdB 
Mouse 
hybridoma 
1 
I.V.  101  93  [81] 
1 Mouse hybridoma cells were generated from HuMAb mice. HuMAb mice are transgenic mice containing human immunoglobulin genes.   
IVIG = intravenous immunoglobulin. I.P. = intraperitoneal. I.V. = intravenous. 
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In another early study examining oral administration of anti-toxin Abs, Lyerly et al. [63] showed 
hamsters could be protected prophylactically from the effects of C. difficile with orally administered 
bovine immunoglobulin G concentrate (BIC), which was generated from the colostrum of cows 
vaccinated with C. difficile culture filtrates. In the post infection model, however, the antibodies had 
no effect on hamsters. Several years later, Kelly et al. [64] produced two bovine IgG preparations by 
immunizing cattle with C. difficile culture filtrates and formalin inactivated TcdA (toxoid A). Both 
preparations were capable of inhibiting TcdA-induced cytotoxicity in in vitro cell assays, as well as 
inhibiting the enterotoxic effects of TcdA on rat intestinal loops. The study did not assess the efficacy 
of bovine IgG preparations in either prophylactic or treatment models.  
In a seminal study, Kink and Williams [65] demonstrated that hens immunized with recombinant 
TcdA and TcdB fragments could yield potent toxin-neutralizing IgY antibodies. As with other studies 
noted above, only anti-TcdA was required for prophylactic protection. However, when IgY antibodies 
specific to both toxins were administered orally to hamsters, the effects were profound: hamsters 
suffering from CDAD were successfully treated and did not show signs of CDAD relapse. This study 
indicated, for the first time, that neutralization of TcdB was important in treatment of CDAD and 
prevention of CDAD relapse. Furthermore, this was one of the most successful examples of oral 
antibody administration, likely due to the robustness of IgY antibodies in withstanding the harsh pH 
and protease-rich gastrointestinal (GI) tract. Elsewhere, Giannasca et al. [66] demonstrated that 
passive immunization of hamsters with immune hamster sera and polyclonal ascites fluid via the I.P. 
route resulted in full protection when administered two days before oral C. difficile challenge. This 
study was one of the first to show systemically delivered anti-toxin antibodies could offer mucosal 
protection from CDAD in hamsters. From this work and that of others, it became obvious that anti-
toxin A and B Abs were required for treatment of CDAD. More recently, van Dissel et al. [67] showed 
bovine immune whey preparations containing toxin-specific sIgA and IgG antibodies from immunized 
cattle were effective at preventing C. difficile-induced hamster mortality when administered orally 
before and after bacterial challenge. Compared to control animals, 80%–90% of hamsters receiving the 
immune whey survived. 
Most of the anti-toxin Ab work reviewed thus far involved antibodies produced from animal 
sources, but for systemic human therapeutics, antibodies should be humanized or of human origin to 
reduce potential immunogenicity. Antibody immunogenicity, however, should not be a concern in the 
oral therapy approach. The first human anti-toxin mAbs specific to TcdA and TcdB were isolated in 
2006 and reported by Babcock et al. [7]. The group evaluated several antibodies, and found that I.P. 
administration of their best TcdA-binding candidate (CDA1) combined with their top TcdB-binder 
(MDX-1388) significantly reduced hamster mortality in the primary CDAD treatment model and 
CDAD relapse model, relative to either mAb alone. Similar to the most efficacious antibodies reported 
before, both CDA1 and MDX-1388 recognized the C-terminal host-cell receptor binding domains of 
TcdA and TcdB, respectively. This work has led to the testing CDA1 and MDX-1388 in the first 
human clinical trial for the treatment of recurrent CDAD, which is discussed below. Toxins 2010, 2                 
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4.3. Experimental human studies  
A number of studies and case reports have indicated that passive immunotherapy is a successful 
therapy for human patients suffering from chronic relapsing C. difficile infection who did not respond 
to standard treatment (i.e., antibiotic therapy). In contrast to animal studies where antibodies were 
delivered orally or systemically, the majority of human studies thus far have used the systemic 
delivery route.  
The earliest reports of treating relapsing CDAD in humans with antibodies were based on 
intravenous immunoglobulin (IVIG) therapy (Table 3). IVIG involves injecting high doses of human 
Ig’s (300–400 mg Ig/kg of body weight) from healthy donors, which are thought to contain TcdA- and 
TcdB-specific antibodies, into patients suffering from CDAD. The first data showing successful 
treatment of relapsing CDAD with IVIG was from Leung et al. [53] who reported five out of five 
children were cleared of their symptoms upon receiving 400 mg IVIG/kg. Others have reported similar 
findings using IVIG therapy with patient survival rates ranging from 60–100%, although these studies 
lacked control subjects [68–75]. Conversely, a retrospective analysis performed by Juang et al. [76] 
concluded that patients administered IVIG (n = 18) showed no statistical advantages over control 
groups (n = 18). More recently, Abougergi et al. [77] reported 9 of 21 patients (43%) receiving IVIG 
for severe CDAD survived, indicating one of the highest mortality rates of IVIG thus far. 
The first case of orally delivered anti-toxin therapy was reported by Tjellström et al. [78] who 
successfully treated a 3½ year old boy with IgA. Recently, a study by van Dissel et al. [67] 
demonstrated the effectiveness of orally delivered bovine immune whey to CDAD patients. Whey 
protein enriched in bovine immunoglobulins was prepared from cattle immunized with inactivated  
C. difficile culture filtrates. Of 15 patients receiving the oral immunoglobulin mixture, 14 were 
completely cured of C. difficile-associated diarrhea. The same group then conducted a larger study and 
found their immune whey treatment successfully prevented CDAD relapse in 98 out of 109 patients [79]. 
Later, Mattila et al. [80] used a similar approach of orally administering bovine immune whey to 
patients suffering from CDAD and found a 55% success rate, although the clinical trial was 
prematurely terminated. The discrepancies between the success rates of the first two immune whey 
studies [67,79] and that conducted by Mattila et al. [80] may be due to differences in the immune whey 
product, patient selection criteria, previous antibiotic usage, and overall study design. 
Collectively, these studies illustrated the effectiveness of polyclonal anti-toxin antibody 
preparations on severe CDAD when administered intravenously or orally to patients. However, a 
major issue with IVIG therapy or bovine immune concentrates is the quantity, quality and variability 
of toxin-specific antibodies contained within these preparations. As such, comparing the effectiveness 
of each of these studies should be treated with caution.  
In a landmark study, Lowy et al. [81] recently provided data on the largest clinical trial involving 
CDAD therapy and the first trial examining the efficacy of human anti-toxin mAbs. The study 
intravenously administered specific doses of both anti-TcdA mAb CDA1 and anti-TcdB mAb CDB1 
or placebo control to 200 patients with recurrent CDAD symptoms. The authors found a significant 
reduction in CDAD recurrence compared to controls, with only 7% of those receiving the mAb 
therapy relapsing compared to a 25% relapse rate among patients receiving placebo.  Toxins 2010, 2                 
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Finally, comparing the efficacy and success rates of the experimental anti-toxin human studies 
described here (summarized in Table 3) should be treated with caution since the study design, study 
endpoints, and success criteria are not uniform.  
4.4. Antibody mechanism of action 
The process of systemically-administered anti-toxin antibodies neutralizing TcdA and TcdB, which 
are found primarily in the colon, is not well understood. Two possible explanations have been 
proposed. First, anti-toxin antibodies administered systemically are thought to migrate to the GI tract 
through a leaky mucosal barrier [57,82]. With many immune centers located in close proximity to the 
mucosa barrier, inflamed or disrupted epithelial cells may allow easy access of systemic Abs to the 
lumen. Alternatively, IgGs may be actively transported from systemic circulation to the lumen via the 
neonatal IgG Fc receptor (FcRn) which is expressed by colonic epithelial cells [82,83]. Both cases are 
supported by an increase in the levels of IgG in the stools from infected patients [50]. It is possible that 
administered Abs may bind and neutralize TcdA/B in the bloodstream, although the principal sight of 
action is believed to be in the GI tract. Regardless of administration route, systemic or oral, at the 
molecular level the mechanism of antibody-based toxin-neutralization in vivo appears to involve 
inhibiting the binding of toxin to target cells, a critical first step in the toxins’ mechanism of   
action (Figure 2). 
5. Future Perspectives for CDAD Immunotherapy 
Many cases documenting the successful treatment of relapsing CDAD with antibody-based reagents 
have relied on systemically-delivery antibody administration. As mentioned above, these antibodies 
likely need to reach the GI tract to work effectively. This brings forth the question: Is systemic 
delivery the most efficacious method for anti-toxin therapy? 
Conceivably, oral-administered toxin-neutralizing antibodies would bypass the need for 
systemically delivered Abs to traverse the mucosal barrier to the GI tract. Currently, there are only a 
handful of examples in the literature suggesting oral therapy may be effective. This may be largely due 
to conventional IgGs being sensitive to the extreme pH and protease-rich environment of the stomach 
and small intestine. Bovine immune Ig preparations [84] and IgA preparations [78] appear to tolerate 
the GI tract as oral administration has proven effective and functional toxin-specific antibodies have 
been recovered after GI tract passage. To enhance the efficacy of orally delivered Abs, the exploration 
of protective antibody formulations and engineered antibodies with robust biophysical properties may 
be warranted. 
5.1. Recombinant antibody fragments 
Antibody fragments (Figure 3) are smaller versions of parent antibodies (i.e., IgGs) that lack one or 
more CH domains while retaining antigen binding capacity. In contrast to conventional antibodies  
(i.e., IgGs) which are produced by traditional immunization approaches, antibody fragments are 
routinely generated through in vitro selection procedures from synthetic/semi-synthetic, naïve, or 
immune display libraries [48,85]. While both methods are equally important for generating therapeutic Toxins 2010, 2                 
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antibodies, recombinant antibody (rAb) fragments offer some advantages. One of the main advantages 
of rAb fragments over conventional antibodies are their amenability to in vitro display selection, which 
circumvents the need for animal immunization and allows for the generation of antibodies against 
targets that are toxic or infectious to the host. In addition, rAbs can be engineered for greater efficacy, 
used as scaffolds or building blocks to generate multi-specific or multivalent antibodies, and used as 
carriers of therapeutic payloads such as radionuclides and toxins. Furthermore, some rAb formats have 
been shown to bind epitopes that are inaccessible with conventional Abs. The most common rAb 
formats include Fab (fragment antigen binding), scFv (single chain variable fragments), and   
single-domain antibodies (see below). Numerous fusion derivatives of these fragments have been 
engineered [86,87].  
There are several reports in the literature of potent toxin neutralization with recombinant antibodies, 
including botulinum toxin, cholera toxin and ricin. With respect to C. difficile toxins, there has only 
been one publication describing the isolation of TcdB binding scFv antibodies [46]. In this work, a 
hyperimmunized scFv library was constructed and provided a source of toxin binders; however, the 
work did not progress beyond binding assays.  
5.2. Single-domain antibodies 
In recent years, smaller antibody fragments have been developed that show considerable promise as 
human therapeutic and diagnostic agents [48,88–90]. Single-domain antibodies (sdAbs) are 
recombinant, in vitro selected fragments and include the VH and VL domains of conventional Igs [91–93], 
the VHH domain from Camelidae species’ heavy-chain IgGs [94–96], and the VNAR domain from 
cartilaginous shark IgNAR antibodies [97]. The unique feature of these antibodies compared to 
conventional antibodies is their small size (13–15 kDa) and single-domain nature which consists of only 
the antigen recognition domain. In addition, sdAbs possess desirable characteristics [98] such as high 
tissue penetrating properties, high chemical, thermal and proteolytic stability, high level expression in 
microorganisms, ease of genetic manipulation and library construction and amenability to in vitro library 
screening and selection under harsh conditions such as proteases [99], acidic pH [100] and heat [101]. 
Because of their small size and the ability to form extended complementarity-determining region 3 
(CDR3) loops, sdAbs can access immunosilent cavities in receptors, enzymes, and infectious   
agents [102–105] that conventional mAbs cannot access, making them novel and potent inhibitors.  
Several VHHs or ‘nanobodies’ have been isolated against targets relevant to infection and   
immunity [89]. Many of these VHHs were effective neutralizers of bacterial toxins, viruses, and 
enzymes, such as: scorpion toxin AahI’ [106]; E. coli heat-labile toxin [107]; foot and mouth   
disease virons [108]; ART2.2, an ecto-enzyme related to ADP-ribosylating bacterial toxins [109]; 
verotoxin 1 [110]; HIV-1 envelope protein gp 120 [111] and rotovirus [112,113]. With their small size, 
access to cryptic epitopes, strong binding affinity which can be well into the low picomolar   
range [114–120], and intrinsic thermal, chemical and protease stabilities, sdAbs could be promising  
C. difficile toxin-neutralizing agents that may exhibit superior efficacy within the GI tract compared to 
conventional formats (i.e., IgG). In addition, the efficacy of these compact antibody formats could be 
further increased by increasing their tolerance to extreme pH and proteolytic degradation through 
engineering and selection-based approaches.  Toxins 2010, 2                 
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6. Conclusions 
With broad-spectrum antibiotic therapy known to promote C. difficile infection and TcdA/B firmly 
established as the causative agents of C. difficile-associated disease, the development of non-antibiotic 
agents to treat CDAD is of considerable importance. The encouraging results from the first human 
clinical trial involving two anti-toxin mAbs demonstrated their efficacy in reducing CDAD relapse 
[81] and further established the importance of anti-toxin neutralizing Abs in controlling CDAD 
severity. Recently, Demarest et al. [121] showed that a panel of mAbs targeting TcdA were potent 
toxin neutralizers, suggesting oligoclonal mixtures of mAbs or Ab fragments targeting unique epitopes 
may be superior toxin neutralizers compared to single mAbs targeting a single epitope. Indeed, this has 
been shown with a panel of anti-botulinum toxin mAbs [122].  
Pharmacokinetics, pharmacodynamics, affinity, specificity and stability are key determinants of 
antibody efficacy in CDAD therapy. Higher affinity antibodies, preferably at least with picomolar KDs, 
should be aimed for, and with respect to specificity, those capable of blocking toxin binding to the host 
epithelia or preventing toxin internalization may prove to be most efficacious. Antibody stability, one 
of the determinants of antibody efficacy in systemic therapy, may be the determining factor of 
antibody efficacy in the oral therapy approach, given that antibodies have to face the hostile 
environment of the GI tract with acid-induced denaturing and protease degradation capabilities. 
Recombinant antibody fragments - in particular single-domain antibodies - lend themselves readily to 
efficacy improvement with regards to all five of the aforementioned antibody characteristics, thanks to 
major advances in the past decades within the field of antibody engineering and evolutionary display 
technologies. Formulation may further protect toxin-specific Abs against the deactivating conditions of the 
GI tract. Plausibly, probiotic bacteria secreting or displaying recombinant antibody fragments [123,124] 
specific for TcdA/B could deliver their toxin-neutralizing payloads directly to the lower GI tract, 
bypassing adverse GI tract conditions and the requirement for purified antibodies altogether.  
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